PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product

On June 15, 2020 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that it has successfully accelerated the development of its Container Closure Integrity (CCI) test– an essential component of the Stability Test required by the U.S. Food and Drug Administration (FDA) (Press release, PharmaCyte Biotech, JUN 15, 2020, View Source [SID1234561104]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, "We are extremely pleased that the company we selected to develop our CCI test was not only successful in the development of the test, but that it was able to complete the development phase of the test much sooner than we anticipated given the test had to be developed from scratch because it is specific to our clinical trial product.

"There were three components to the development of our CCI test, and fortunately, each component was developed without a single setback. Now, we’re in a position to run the CCI test according to the method developed."

The FDA specifically required a CCI test be run on pre-filled syringes containing 300 cellulose sulphate microcapsules in 2mls of freezing medium, and then the data from the CCI test be included in PharmaCyte’s Investigational New Drug application (IND). Initially, PharmaCyte was prepared to submit the IND with the CCI test data following the IND submission. Because we envisioned the CCI test taking much longer to develop, we planned to use the data from the sterility test as a surrogate for the CCI test. However, use of a surrogate may no longer be required.

The first developmental phase of the CCI test was to develop a High Voltage Leak Detection (HVLD) program setup and feasibility study. The objective was to develop a preliminary leak test method with the capability of differentiation of the PharmaCyte syringe system with 5μm defects and those without 5μm defects. These parameters were utilized for performance qualification and functioned to verify the use of the PharmaCyte system with a HVLD instrument.

The second developmental phase of the CCI was to develop the method for such a HVLD system. The method development included using a PTI E-Scan HVLD leak test instrument with a sample set of laser-drilled defects (small manually created holes on the sides of several syringes) and use of syringes with no known defects at all. Certain parameters were used for optimization. The method was developed using PharmaCyte’s filled syringes. A representative placebo was also utilized. The final product was verified in development prior to the validation with the optimized parameters.

The third developmental phase was to validate a leak test method using HVLD technology. All work was completed using a PTI E-Scan HVLD leak test instrument. Validation included three test series across multiple days and operators.

Now all that remains is the development of a protocol by which frozen samples of PharmaCyte’s clinical trial product will be tested employing the validated high voltage method for PharmaCyte’s syringe system for container closure integrity over time. That work is underway.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: View Source

Epigenomics AG to Participate in Raymond James Human Health Innovations Conference

On June 15, 2020 Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the "Company") reported that company management will be presenting at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020, at 9:40 am (ET) / 3:40 pm (CET) and invites investors to participate by webcast (Press release, Epigenomics, JUN 15, 2020, View Source [SID1234561120]). The webcast can be accessed in the investor relations section of Epigenomics’ website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

On June 15, 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that it will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020 (Press release, Neurocrine Biosciences, JUN 15, 2020, View Source [SID1234563734]). Kevin Gorman, Chief Executive Officer, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

Kyowa Kirin makes POTELIGEO® (mogamulizumab) available in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome, Two Rare Forms of Non-Hodgkin’s Lymphoma with High Unmet Medical Need

On June 15, 2020 Kyowa Kirin Co., Ltd., (Kyowa Kirin) reported commercial availability of POTELIGEO (mogamulizumab) in Germany for the treatment of adult patients with the rare cancers, mycosis fungoides (MF) and Sézary syndrome (SS), who have received at least one prior systemic therap (Press release, Kyowa Hakko Kirin, JUN 15, 2020, View Source [SID1234561089])y.1 POTELIGEO is a first-in-class humanised monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4), 2 a protein consistently expressed on cancerous cells seen in both MF and SS; 3,4,5 once POTELIGEO binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.6

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MF and SS are subtypes of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin’s lymphoma7 that can affect the skin, blood, lymph nodes and internal organs. 8 CTCL is rare. For every 100,000 people, there are approximately 24cases of CTCL.9 The annual incidence of MF in Europe is estimated to be between 1 in 110,000 to 1 in 350,000.10 The annual incidence of SS is 1 in 10,000,000.11 Together they represent approximately 65% of all cases of CTCL. 8 Individuals with this disease often suffer from disfiguring, itchy, painful and unpredictable skin symptoms, which can lead to further complications that can impact their life expectancy.2,12 POTELIGEO, which demonstrates improvement in these skin and disease-related symptoms, as well as control of the disease, is expected to be available for prescription in Germany from 15th June 2020 2

"CTCL substantially deteriorates the quality of life for those living with the disease, as it has a profound and severe impact on daily function and social interactions" said Abdul Mullick, President of Kyowa Kirin International. "By making POTELIGEO available in Germany, we are helping meet the needs of physicians and patients to manage MF and SS more effectively. This milestone demonstrates the steady advances we are making as a company to fulfil the requests of patients suffering from diseases for which there are limited adequate treatments. We are continuing discussions with local health authorities across Europe in order to bring this treatment to more and more patients as quickly as possible". 2 Professor Chalid Assaf, Head of the Department of Dermatology, Helios Klinikum Krefeld, Germany said "POTELIGEO more than doubled the median progression-free survival of affected patients compared to vorinostat. 1 In particular, skin and blood responded significantly to the treatment, with lasting effects. The results are based on the MAVORIC study, the largest clinical trial to date on mycosis fungoides and Sézary syndrome."

About Mycosis Fungoides (MF) and Sézary Syndrome (SS) MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin. 13,14 These cancerous T cells consistently express a protein called CC-chemokine receptor 4 (CCR4), which enables them to move from the blood to the skin. 3,4,5 When these cancerous T cells move to the skin, they can create a localised inflammatory immune skin response, commonly resulting in visible skin symptoms of red patches or plaques3,15,16,17,18 which can resemble psoriasis or eczema.13

MF and SS can affect the skin, blood, lymph nodes (part of the body’s immune system which is spread throughout the body) and internal organs.8 All four areas of the body are used to assess disease stage,19,20 and clinically significant involvement of the blood, particularly in more advanced disease, is linked with increased morbidity and an overall reduction in patient survival.19,21,22

Due to its likeness to more common skin conditions such as eczema and psoriasis,13 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis. 23 It is critical for doctors to diagnose CTCL as early as possible as the patient’s prognosis can be affected if the disease progresses to later stages.24 Whilst most individuals that present with early stage do not progress to a more severe stage, 25 patients with advanced disease have significantly poorer outcomes with only around half of patients (52%) surviving for just 5 years.19

About POTELIGEO (mogamulizumab)
POTELIGEO is a first-in-class humanised monoclonal antibody (mAb), designed to bind to CC chemokine receptor 4 (CCR4).2 After POTELIGEO binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.6 POTELIGEO uses Kyowa Kirin’s proprietary POTELLIGENT technology, which enhances the body’s natural immune reaction to treatment, resulting in improved efficacy for killing cancer cells.6 1Vorinostat is a USA FDA-licensed existing treatment for MF and SS and is currently unlicensed in the EU 3 The European Commission (EC) granted marketing authorisation for POTELIGEO in November 2018 for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.1 The European Medicines Agency’s (EMA) decision was based on results of the MAVORIC trial, the largest study conducted in MF and SS, 2 and the first trial to compare systemic therapies using progression-free survival as a primary endpoint, which is a robust endpoint for a CTCL study, as it incorporates looking at disease progression in four different areas of the body (skin, blood, lymph nodes and internal organs).2

About the MAVORIC Trial 
The MAVORIC trial is the largest study conducted in MF and SS,2 and the first trial to compare systemic therapies using ‘progression-free survival’ (PFS) as a primary endpoint, which is a robust endpoint for a CTCL study, as it incorporates looking at disease progression in four different areas of the body (skin, blood, lymph nodes and internal organs).2

 Secondary endpoints were overall response rate; duration of response (time from first achievement of an overall response to progression or death); the proportion of patients with an overall response in the crossover portion of the trial; assessment of quality of life; immunogenicity (immune response) and safety.2

 Results showed that: o People taking POTELIGEO experienced control over their disease for more than twice as long as those taking the comparator treatment, vorinostat* (PFS of 7.7 mths vs 3.1 mths) (HR=0.53, 95% CI: 0.41–0.69; p<0.0001).

2 o Overall significantly more patients responded to POTELIGEO than vorinostat* (Overall Response Rate [ORR] 28% versus 5%; Risk Ratio [RR]: 23.1; 95% CI 12.8-33.1, P<0.0001).2 o Response to treatment lasted 43% longer in people taking POTELIGEO versus those taking vorinostat* (14.1 months versus 9.1 months).2

 Significant involvement in the blood in MF/SS patients is linked to poorer predicted disease outcomes. 19,21,22 o More patients responded to POTELIGEO, across all studied MF/SS disease stages than with vorinostat.*

2 POTELIGEO has overall good tolerability with a manageable safety profile.2,26 o The most common adverse reactions with POTELIGEOare constipation, diarrhoea, nausea, stomatitis, fatigue, oedema peripheral, pyrexia, infections, infusion related reactions, headache and drug eruption (including skin rash).1.

* Vorinostat is a USA FDA-licensed existing treatment for MF and SS and is currently unlicensed in the EU 4 Important Safety Information Refer to the full Product Information for human medicinal products for full safety information: View Source Kyowa Kirin International PLC, a Kyowa Kirin Group company, is responsible for commercialising POTELIGEO in Europe.

Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

On June 15, 2020 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for BPX-603 (Press release, Bellicum Pharmaceuticals, JUN 15, 2020, View Source [SID1234561105]). BPX-603 is a GoCAR-T product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates both the company’s iMC activation and CaspaCIDe safety switch technologies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The FDA’s clearance of our IND for BPX-603 marks a significant milestone for Bellicum, adding a second clinical program to further evaluate our novel GoCAR-T technology’s ability to enhance CAR-T and host immune cell activity against solid tumors," said Rick Fair, President and Chief Executive Officer of Bellicum. "We look forward to initiating our Phase 1/2 trial with BPX-603 targeting solid tumors that express HER2 later this year."

HER2 is a validated antigen for cancer therapies and academic CAR-T cell clinical studies have shown evidence of modest antitumor activity. BPX-603 was designed to improve upon these efforts, primarily through incorporation of the inducible co-activation domain MyD88/CD40, or "iMC". MC signaling is believed to boost effector cell proliferation and survival; enhance functional persistence by resisting exhaustion and the suppressive tumor microenvironment; and stimulate the cancer patient’s own immune system. Additionally, Bellicum’s dual-switch technology—which enables the clinician to either activate or eliminate GoCAR-T cells with the administration of small molecules—is designed to enhance real-time control of both efficacy and safety.